Therapy for Children With Neuroblastoma

Part of paid clinical trials in Memphis, Tennessee.

Sponsor
St. Jude Children's Research Hospital
Study ID
NCT00135135
Phase
PHASE2
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
N/A - 18 Years
Healthy Volunteers
Not accepted

Interventions

Study Details

This is a phase II window study of the combination of ZD1839 (gefitinib) and irinotecan in children with high-risk neuroblastoma followed by standard induction chemotherapy, intensification with autologous stem cell transplantation, and an oral maintenance phase with 13-cis-retinoic acid and topotecan. We hypothesize that the ZD1839 (gefitinib) and irinotecan window will be efficacious.

Key Dates

Start date
Aug 31, 2005
Status verified
Jun 2008
Primary completion
Jun 30, 2007
Completion
Jun 30, 2007

Study Design

Enrollment
23 participants (actual)
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Other: 1

Primary Outcome Measure

Response rate [ Time Frame: Within 30 days of completion of window therapy. ]

Locations (1)

FacilityCityStateZIPSite coordinators
St. Jude Children's Research HospitalMemphisTennessee38105-

Find similar trials in Memphis, TN

By condition
Neuroblastoma
By specialty
OncologyPediatric oncology
By research site
St. Jude Children's Research Hospital· Memphis, TN

Related Studies